Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP
- 13 February 2002
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 17 (2) , 303-312
- https://doi.org/10.1002/mds.10042
Abstract
It is often difficult to differentiate clinically between Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP).The objective of this work was to investigate whether combined pre‐ and postsynaptic dopaminergic single photon emission computed tomography (SPECT) scanning can reliably demonstrate changes in the nigrostriatal dopaminergic system and help differentiate between normal controls, PD, MSA, and PSP patients. We performed SPECT evaluation of the dopamine transporter (DAT) and dopamine D2 receptors (D2). SPECT scans using [123I]β‐CIT (for DAT) and [123I]IBF (for D2) were performed in 18 patients with PD (12 dopa‐naïve and 6 on levodopa and/or dopamine agonists), 7 with MSA of the striatonigral degeneration type, 6 with PSP, and 29 normal controls. Antiparkinsonian drugs were withheld for at least 12 hours before the scans. DAT and D2 binding potentials (Rv = V3/V2) were measured for caudate, anterior, and posterior putamen on the sides ipsilateral and contralateral to the worst motor symptoms. DAT binding in the posterior putamen was markedly reduced in all patients. However, D2 binding in posterior putamen was significantly increased in dopa‐untreated PD, being greater than the normal range in 4 of 12 (33%), and it was significantly reduced in MSA, being below the normal range in 5 of 7 (71%). None of the patients with PD showed reduced D2 binding below the normal range in posterior putamen. The degree of DAT binding could not discriminate between the patient groups. The ratio of posterior putamen to caudate percentage D2 Rv compared with the controls showed an opposite pattern between PD or PSP and MSA; the caudate was greater in 16 of 18 with PD and 6 of 6 with PSP, whereas caudate was less in 5 of 7 with MSA. These findings suggest that DAT SPECT may be useful in differentiating parkinsonism from controls and D2 SPECT in further differentiating MSA from Parkinson's disease and possibly PSP. © 2002 Movement Disorder Society.Keywords
This publication has 45 references indexed in Scilit:
- 123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonismMovement Disorders, 1998
- Dystonia in progressive supranuclear palsy.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomographyAnnals of Neurology, 1996
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)Neurology, 1996
- Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2′-ISP in nonhuman primatesNuclear Medicine and Biology, 1994
- Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's diseaseAnnals of Neurology, 1993
- THE RELATIONSHIP BETWEEN LOCOMOTOR DISABILITY, AUTONOMIC DYSFUNCTION, AND THE INTEGRITY OF THE STRIATAL DOPAMINERGIC SYSTEM IN PATIENTS WITH MULTIPLE SYSTEM ATROPHY, PURE AUTONOMIC FAILURE, AND PARKINSON'S DISEASE, STUDIED WITH PETBrain, 1990
- Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's DiseaseNew England Journal of Medicine, 1988
- L-DOPA reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatumJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985